Toronto Stock Exchan • Healthcare • Biotechnology • CA • CAD
Trillium Therapeutics Inc. (TRIL.TO) has a consensus analyst rating of Hold, based on 5 analysts covering the stock. Of those, 2 recommend buying, 3 recommend holding, and 0 recommend selling.
No price target data available.
Be the first to know when stocks drop below their intrinsic value.
